XClose

Euro Ewing Consortium

International Clinical Trials to Improve Survival from Ewing Sarcoma
Menu

rEECur - Information for patients and carers


The aim of the rEECur trial is to compare four different chemotherapy regimens to find out which is most effective and/or has fewest side effects.

Why is this trial being run?

The trial is comparing four treatments, also known as regimens or arms, called TC, IT, GD and IFOS. These regimens are four commonly used treatments for recurrent Ewing sarcoma. The trial is being run as it is not known which is the best treatment for this group of patients.

Can I take part in the trial?

If you have Ewing sarcoma that has come back after treatment or have primary Ewing sarcoma that is not responding to therapy, you may be able to take part in the trial. Your doctor will explain whether you are able to take part. Your doctor will review your diagnostic tests and medical notes to see if you are eligible to take part in the trial.

What treatment will I receive?

Topotecan and cyclophosphamide (TC)

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

Irinotecan and temozolomide (IT)

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

Gemcitabine and docetaxel (GD)

If you are in this group you will receive at least six cycles of chemotherapy. This means that every three weeks you will have chemotherapy on one day in the first week and then on one day in the second week of each treatment cycle and this will happen six times. Once you have completed the six cycles your doctor may choose to give you some more treatment, either more chemotherapy, radiotherapy or surgery.

Ifosfamide (IFOS)

If you are in this group you will receive four cycles of chemotherapy. This means that every three weeks you will have chemotherapy for five days in a row and this will happen four times. Once you have completed the four cycles your doctor may choose to give you some more treatment.


For more detailed information, please go to the following websites:

Country Website
UK
Cancer Research UK
Spain
Registro espanol de estudios clinicos

Can I choose which treatment arm I receive?

No. rEECur is a randomised trial so you will be randomly assigned to a treatment arm by a computer. This is done so that neither you nor your doctor will be able to influence which treatment arm you receive and means that the results of the trial are not biased in any way.

Where is the trial running?

At present (August 2015), the trial is recruiting patients at hospitals in the following locations and will open in other countries outside of the UK, Spain, Italy and Norway over the next months:

UK

Birmingham
Birmingham Children’s Hospital
Liverpool
Alder Hey Children's Hospital, Liverpool
Clatterbridge Centre for Oncology, Wirral
London
University College London Hospital
Manchester
Central Manchester University Hospitals
The Christie Hospital, Manchester
Nottingham
Nottingham University Hospitals NHS Trust
Sheffield
Sheffield Children's Hospital

Spain

Barcelona Hospital de la Santa I Sant Pau
Hospital U Vall d’Hebron
Bilbao
Hospital de Cruces
Madrid
Hospital La Paz
Malaga
Hospital Clinico Virgen de la Victoria
Oviedo
Hospital Central de Asturias
Seville
Hospital Virgen del Rocio
Tenerife
Hospital Canarias
Valencia
Hospital Universitario Politécnico La Fe
Hospital Politécnico U La Fe

Italy

Bologna Instituto Ortopedico Rizzoli

Norway

Bergen Haukeland University Hospital
Oslo
Oslo University Hospital Paediatrics & Adults
Trondheim
St Olavs Hospital Paediatrics & Adults
Tromsø
University Hospital Norway Paediatrics & Adults

How many patients will take part?

525 patients will be recruited from across Europe between 2015 and 2018.

How can I find out more information?

  • Read more at Cancer Research UK
  • Print out this information and discuss it with your doctor who will be able to find out more information for you - rEECur patient information (pdf)

How can I take part in the trial?

Talk about the trial with your doctor who will find out if you are eligible and if so, help you to take part.

If you have any questions about this trial, please contact the Cancer Research UK Clinical Trials Unit at the University of Birmingham reecur@trials.bham.ac.uk
***The Trial Office cannot give advice on personal clinical questions***